Publisher
Springer Science and Business Media LLC
Reference13 articles.
1. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thürlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M, Arimidex Writing Committee, Investigators Committee Members (2001) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92: 2247–2258
2. Buzdar A (2004) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group. J Clin Oncol 22: 3199–3200
3. Buzdar AU (2002) Superior efficacy of letrozole versus tamoxifen as first-line therapy. J Clin Oncol 20: 876
4. Goss PE (2004) NCIC CTG MA.17 final analysis of updated data: a placebo-controlled trial of letrozole following tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer. Available at http://www.asco.org/ac/1,100,_12-002511-00_18-0026-00_19-0011301,00.asp . Accessed 10 Nov 2004
5. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349: 1793–1802
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献